Prot #CO-1686-022: TIGER 1: A Randomized, Open-Label, Phase II Study of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)

Project: Research project

Project Details

StatusFinished
Effective start/end date12/11/1412/11/17

Funding

  • PRA Health Sciences (Prot #CO-1686-022)
  • Clovis Oncology, Inc. (Prot #CO-1686-022)